Climb Bio (NASDAQ:CLYM - Get Free Report) was upgraded by stock analysts at BTIG Research to a "strong-buy" rating in a research report issued on Thursday, Marketbeat reports. The firm presently has a $7.00 price target on the stock. BTIG Research's price objective would suggest a potential upside of 483.33% from the company's previous close.
Climb Bio Stock Down 0.8%
Shares of CLYM opened at $1.20 on Thursday. The stock has a market cap of $81.09 million, a PE ratio of -0.56 and a beta of -0.12. The firm's fifty day moving average price is $1.25. Climb Bio has a twelve month low of $1.05 and a twelve month high of $9.58.
Climb Bio (NASDAQ:CLYM - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.16). On average, analysts predict that Climb Bio will post -1.57 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of CLYM. Bank of New York Mellon Corp bought a new position in shares of Climb Bio in the 1st quarter worth about $79,000. Peapod Lane Capital LLC bought a new position in shares of Climb Bio in the 1st quarter worth about $676,000. TD Asset Management Inc bought a new position in shares of Climb Bio in the 1st quarter worth about $109,000. XTX Topco Ltd bought a new position in shares of Climb Bio in the 1st quarter worth about $34,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of Climb Bio in the 1st quarter worth about $86,000. 69.76% of the stock is currently owned by institutional investors.
Climb Bio Company Profile
(
Get Free Report)
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Further Reading
Before you consider Climb Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.
While Climb Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
